Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: Methylene blue and amotosalen

Transfusion

Volumn 48, Issue 1, 2008, Pages 108-117

  Osselaer, Jean Claude ^a   Debry, Cécile ^b   Goffaux, Maite ^b   Pineau, Jacqueline ^b   Calomme, Genevieve ^b   Dubuc, Eric ^b   Chatelain, Bernard ^b   Vandendaele, Marie Claire ^b   Hsu, Jocelyn ^b   Rheinschmidt, Margaret ^b   Lin, Lily ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRINOGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMIN INHIBITOR; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

APHERESIS; ARTICLE; BELGIUM; BLOOD CLOTTING; BLOOD COMPONENT; BLOOD GROUP ABO SYSTEM; BLOOD STORAGE; BLOOD TRANSFUSION; CONTROLLED STUDY; HUMAN; LIGHT; PATHOGEN INACTIVATION; PHOTOCHEMISTRY; PROTHROMBIN TIME; QUALITY CONTROL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STORAGE TEMPERATURE; STUDENT T TEST; THAWING; THROMBIN TIME; THROMBOPLASTIN TIME; ULTRAVIOLET RADIATION;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; HUMANS; LIGHT; METHYLENE BLUE; PHOTOCHEMISTRY; PLASMA; PSORALENS; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 37549049779     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01488.x     Document Type: Article

References (33)

1. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 9.
2. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004 44 : 1496 504.
3. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 45 : 580 90.
4. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001 38 (4 Suppl 11 4 11.
5. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006 46 : 1168 77.
6. Muller-Breitkreutz K, Mohr H, Briviba K, Sies H. Inactivation of viruses by chemically and photochemically generated singlet molecular oxygen. J Photochem Photobiol B 1995 30 : 63 70.
7. Lin L, Conlan MG, Tessman J, Tessman J, Cimino G, Porter S. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005 45 : 1610 20.
8. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003 47 : 475 9.
9. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Voorhis WC. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005 45 : 1459 63.
10. Castro E, Gironés N, Bueno JL, Carrion J, Fresno M. The efficacy of photochemical treatment with amotosalen and UVA (INTERCEPT) for the inactivation of Trypanosoma cruzi (T. cruzi) in buffy coat derived platelet components. Vox Sang 2006 91 (S3 176.
11. Girones N, Bueno JL, Carrion J, Fresno M, Castro E. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006 91 : 285 91.
12. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion 1994 34 : 521 6.
13. Aznar JA, Molina R, Montoro JM. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 1999 39 : 748 50.
14. Garwood M, Cardigan RA, Drummond O, Hornsey V, Turner CP, Young D, Williamson LM, Prowse CV. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003 43 : 1238 47.
15. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001 11 : 31 6.
16. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998 74 (Suppl 1 219 23.
17. Heiden M, Seitz R. Quality of therapeutic plasma-requirements for marketing authorization. Thromb Res 2002 107 (Suppl 1 S47 51.
18. Solheim B. Composition, efficacy, and safety of S/D-treated plasma. Transfusion 2003 43 : 1176 8.
19. Beach KJ. Important prescribing information [monograph on the Internet]. Watertown (MA) : V.I. Technologies, Inc. (VITEX) 2000 Oct 20. Available from: http://www.fda.gov/medwatch/safety/2000/plassd.pdf
20. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000 15 : 169 72.
21. Yarranton H, Cohen H, Pavord SR, Benjamin S, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003 121 : 778 85.
22. Pock K, Heger A, Janisch S, Svae T-E, Romisch J. Thrombin generation capacity is significantly impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a pharmaceutically licensed coagulation active plasma (Octaplas), and a development product (Uniplas) [abstract]. Proceedings of Pathogen Inactivation Consensus Conference Toronto, Canada 2007 Mar 29-30.
23. Politis C, Kavallierou L, Hantziara S, Katsea, P, Triantaphylou V, Richardson C, Tsoutsos D, Anagnostopoulos N, Gorgolidis G, Ziroyannis, P. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007 92 : 319 26.
24. Alvarez-Larran A, Del Rio J, Ramirez C, Albo C, Peña, F, Campos A, Cid J, Muncunill J, Sastre J-L, Sanz C, Pereira A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004 86 : 246 51.
25. de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA. Role of methylene blue-treated or fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001 114 : 721 3.
26. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001 41 : 1548 52.
27. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005 45 : 1362 72.
28. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006 107 : 3753 60.
29. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza, I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan M. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006 46 : 1693 704.
30. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003 85 : 171 82.
31. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol 2001 38 (4 Suppl 11 12 9.
32. Wagner SJ, Cifone MA, Murli H, Dodd RY, Myhr B. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion 1995 35 : 407 13.
33. Hejtmancik MR, Ryan MJ, Toft JD, Persing RL, Kurtz PJ, Chhabra RS. Hematological effects in F344 rats and B6C3F1 mice during the 13-week gavage toxicity study of methylene blue trihydrate. Toxicol Sci 2002 65 : 126 34.